Unusual volume stocks in Tuesday's session
By Mill Chart
Last update: Jan 24, 2023
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
Unusual volume stocks
| Ticker | Change | Comment |
|---|---|---|
| GNS | 1.06% | 56.73M shares of GENIUS GROUP LTD (NYSEARCA:GNS) have been traded so far today. Shares are rising by 1.06%. This is 304.0% above the average daily volume of the last 50 days. A press release (Genius Group 2023 Financial Guidance: $48m - $52m Revenue, Positive EBITDA) was released yesterday. |
| INBS | 11.79% | INTELLIGENT BIO SOLUTIONS IN's (NASDAQ:INBS) traded a high volume of 22.89M shares. Shares are rising by 11.79%. This volume is 660.0% above the average 50 day volume. |
| IDAI | -3.16% | 863.1K shares of T STAMP INC-CLASS A (NASDAQ:IDAI) exchanged hands today. NASDAQ:IDAI is declining 3.16% today. The average volume measured over 50 days is 415.48K, so this is 108.0% above the average volume. |
| OTRK | 20.57% | 5.58M shares of ONTRAK INC (NASDAQ:OTRK) exchanged hands today. NASDAQ:OTRK is advancing 20.57% today. This is 23.79% above the average daily volume of the last 50 days. |
| BTB | 4.27% | So far 3.45M shares of BIT BROTHER LTD (NASDAQ:BTB) have traded in today's session. Leading to a price increase of 4.27%. This is 65.86% above the average daily volume of the last 50 days. |
| TCRX | -3.85% | TSCAN THERAPEUTICS INC (NASDAQ:TCRX) has an unusual volume of 376.97K shares today. NASDAQ:TCRX is declining 3.85% today. The average daily volume over 50 days is 149.29K, so this is 153.0% above the average volume. A press release (TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors) was released yesterday. |
| HLBZW | -7.2% | 402.36K shares of HELBIZ INC-CW24 (NASDAQ:HLBZW) exchanged hands today. Leading to a price decrease of 7.2%. The average daily volume over 50 days is 101.93K, so this is 295.0% above the average volume. |
| AZ | -12.15% | 192.1K shares of A2Z SMART TECHNOLOGIES CORP (NASDAQ:AZ) exchanged hands today. The share price decreased by 12.15%. The average daily volume over 50 days is 127.08K, so this is 51.17% above the average volume. |
| FAZE | -5.75% | FAZE HOLDINGS INC (NASDAQ:FAZE) has an unusual volume of 658.35K shares. NASDAQ:FAZE is declining 5.75% today. The average volume measured over 50 days is 258.52K, so this is 155.0% above the average volume. |
| VERB | -47.63% | 36.71M shares of VERB TECHNOLOGY CO INC (NASDAQ:VERB) have been traded so far today. NASDAQ:VERB is declining 47.63% today. This is 657.0% above the average daily volume of the last 50 days. |
Our unusual volume stocks screener will show you the full list.
TSCAN THERAPEUTICS INC
NASDAQ:TCRX (4/25/2024, 4:20:00 PM)
After market: 7.43 +0.14 (+1.92%)7.29
-0.09 (-1.22%)
TCRX News
a day ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingWALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
a day ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesWALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
3 days ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingWALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
6 days ago - Market News VideoInvestors Snatch TCRX 6.7% Lower Than Its Secondary Stock Offering6 days ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Closing of Upsized Public OfferingWALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
9 days ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering9 days ago - TScan Therapeutics, Inc.TScan Therapeutics Announces Launch of $125 Million Proposed Public OfferingWALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
